Market news

ABIVAX Société Anonyme (ENXTPA:ABVX) has just paired deeper operating cash use and wider losses with fresh leadership hires and extended funding, creating a complex backdrop for anyone tracking the stock today. Recent moves have come against a tougher tape for ABIVAX Société Anonyme, with the share price down 28.78% year to date and 15.91% over 30 days, even as the 1 year total shareholder return of 16.50% and the very large 3 year total shareholder return of 446.00% point to longer term...

ABIVAX Société Anonyme (ENXTPA:ABVX) has appointed a new Chief Medical Officer and a new Chief Technical Officer. The fresh leadership roles are focused on medical strategy, product development and technical operations across Abivax SA's pipeline. The appointments are intended to support the firm's efforts around clinical programs and preparation for potential commercialization activities. The appointment of a new Chief Medical Officer and Chief Technical Officer should not be the only...

Abivax is advancing obefazimod for ulcerative colitis and Crohn’s, with recent safety concerns now largely addressed. Read more on ABVX stock here.

Abivax missed EPS estimates but beat sales in H1; shares dipped. Wedbush and Truist cut price targets to $118 and $151.

Abivax (ABVX) has an average rating of buy and mean price target of $164.20, according to analysts p

Abivax (ABVX) said Monday Fabio Cataldi will be leaving the company in the fourth quarter of 2026, a

Companies Reporting Before The Bell • Ennis (NYSE:EBF) is expected to report earnings for its second quarter. Companies Reporting After The Bell • Abivax (NASDAQ:ABVX) is projected to report quarterly loss at $1.08 per

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Abivax (ABVX) has an average rating of buy and mean price target of $162.06, according to analysts p

Abivax SA Sponsored ADR (ABVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis...

ABIVAX Société Anonyme (ENXTPA:ABVX) has drawn fresh attention after expanding its commercial leadership team by adding four senior executives across marketing, patient services, sales and commercial operations, and market access for its lead candidate, obefazimod. See our latest analysis for ABIVAX Société Anonyme. Those commercial hires and the recent R&D collaboration with Valerio Therapeutics come after a period where ABIVAX Société Anonyme’s 1 month share price return of 33.49% contrasts...

Abivax has expanded its Commercial Leadership Team to prepare for potential U.S. commercialization of obefazimod. The company has agreed a binding term sheet for an exclusive worldwide R&D collaboration with Valerio Therapeutics to develop next generation immune mediated inflammatory disease therapies. The moves combine commercial build out with access to RNA technology platforms and new therapeutic candidates. ABIVAX Société Anonyme (ENXTPA:ABVX) is stepping up its U.S. ambitions as it...

VILLEJUIF, France, July 16, 2026--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), today announces that it has entered into a binding term-sheet with Abivax SA ("Abivax"), setting out the principal terms of an exclusive worldwide research and development collaboration. The final terms remain subject to the signing of the definitive co-ownership and license agreement.

July 15 (Reuters) - Shares of Celcuity fell about 8% in premarket trading on Wednesday, as the delayed commercial launch of its newly approved breast cancer drug and treatment-tolerability concerns

Detailed price information for Anaptysbio Inc (ANAB-Q) from The Globe and Mail including charting and trades.

The French biotech plans to use proceeds to commercialize obefazimod in the U.S. through 2029, CEO Marc de Garidel told CNBC

Its latest fundraising round provides the French biotech with enough cash to finance operations through 2029.

Abivax stock surged over 40% after positive Phase 3 data on ulcerative colitis drug Obefazimod and a $920 million share offering that underwriters fully exercised, signaling strong institutional demand.

Is ABVX a good stock to buy? We came across a bullish thesis on ABIVAX Société Anonyme on R. Dennis’s Substack by OppCost. In this article, we will summarize the bulls’ thesis on ABVX. ABIVAX Société Anonyme’s share was trading at $133.26 as of June 30th. ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness […]